Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Transoma Medical IPO: Maker of the Sleuth implantable electrocardiogram monitoring system announces Oct. 12 plans for an initial public offering of up to $75 million in common stock. The Sleuth system, which "captures, records, analyzes and wirelessly transmits clinically relevant ECG data," debuted earlier this month following an Oct. 1 510(k) clearance. The system is intended for monitoring patients with clinical syndromes or increased risk of cardiac arrhythmias, as well as patients "who experience transient symptoms that may suggest a cardiac arrhythmia," the firm says (1"The Gray Sheet" Jan. 1, 2007, p. 21). By 2009, Transoma plans to release an enhanced version for diagnosing and monitoring atrial fibrillation. Future generation systems also will enable stratification of patients at risk of sudden cardiac death and long-term monitoring of blood pressure, the firm says. Transoma generated revenue of $37.2 million for the 12 months ended June 30, up 20.5%, based on use of its technology in animal models for biomedical research. Underwriters for the IPO include Piper Jaffray, Thomas Weisel Partners, RBC Capital Markets, Canaccord Adams and BMO Capital Markets
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT025388

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel